Windtree Net Income from 2010 to 2024
| WINT Stock | USD 0.50 0.01 1.96% |
Net Loss | First Reported 1995-03-31 | Previous Quarter 10.2 M | Current Value -12 M | Quarterly Volatility 5.9 M |
Check Windtree Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Windtree Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 77.9 K, Interest Expense of 47.5 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 633, Dividend Yield of 0.0 or PTB Ratio of 0.8. Windtree financial statements analysis is a perfect complement when working with Windtree Therapeutics Valuation or Volatility modules.
Windtree | Net Income |
Latest Windtree Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Windtree Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Windtree Therapeutics financial statement analysis. It represents the amount of money remaining after all of Windtree Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Windtree Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Windtree Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (20.29 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Windtree Net Income Regression Statistics
| Arithmetic Mean | (32,838,303) | |
| Coefficient Of Variation | (50.18) | |
| Mean Deviation | 13,096,517 | |
| Median | (30,280,000) | |
| Standard Deviation | 16,477,656 | |
| Sample Variance | 271.5T | |
| Range | 64.8M | |
| R-Value | (0.11) | |
| Mean Square Error | 288.8T | |
| R-Squared | 0.01 | |
| Significance | 0.70 | |
| Slope | (406,203) | |
| Total Sum of Squares | 3801.2T |
Windtree Net Income History
Other Fundumenentals of Windtree Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Windtree Therapeutics Net Income component correlations
About Windtree Therapeutics Financial Statements
Windtree Therapeutics shareholders use historical fundamental indicators, such as Net Income, to determine how well the company is positioned to perform in the future. Although Windtree Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Windtree Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Windtree Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -20.3 M | -21.3 M | |
| Net Loss | -20.3 M | -21.3 M | |
| Net Loss | -60.9 M | -63.9 M | |
| Net Loss | (92.23) | (96.84) | |
| Net Income Per E B T | 1.11 | 1.13 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.